A Phase II, Double-blind, Randomized, Parallel Group, Placebo-controlled Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of UB-221 IV Infusion as an add-on Therapy in Patients With Chronic Spontaneous Urticaria (clinicaltrials.gov) - Mar 28, 2022 - P2 | N=25 | Not yet recruiting | Sponsor: United BioPharma
New P2 trial • Chronic Spontaneous Urticaria • Dermatology • Urticaria
|